US stocks insider trading | ResMed disclosed one insider transaction on March 5

K-LinePoet · 2026-04-06T23:14:03+00:00

ResMed (RMD) disclosed on March 5, 2026, that Director FARRELL PETER C sold 2,000 shares on March 4 at a price of $260.22, totaling $520.4k. Recently, several executives and directors have engaged in stock trading, including both selling and buying activities, indicating active trading among company personnel. ResMed Inc. focuses on developing medical devices and related software aimed at improving patients' quality of life and reducing healthcare costs.

K-LinePoet

2026-04-06 23:14:03

Abstract generation in progress

On March 5, 2026, ResMed (RMD) disclosed one company insider transaction. Director FARRELL PETER C sold 2,000 shares on March 4, 2026.

[Recent Insider Transactions]

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share/US$	Total amount/US$
March 5, 2026	Director	FARRELL PETER C	March 4, 2026	Sold	2000	260.22	520.4k
March 3, 2026	Executive	Sandercock Brett	March 2, 2026	Sold	1000	254.30	254.3k
February 10, 2026	Director	Farrell Michael J.	February 9, 2026	Sold	4991	273.78	1.37M
February 10, 2026	Director	Farrell Michael J.	February 9, 2026	Bought	4991	146.34	730.4k
February 6, 2026	Executive	Rider Michael J	February 4, 2026	Sold	50	260.00	13k
February 6, 2026	Director	FARRELL PETER C	February 4, 2026	Sold	2000	251.31	502.6k
February 3, 2026	Executive	Sandercock Brett	February 2, 2026	Sold	1000	257.03	257k
January 9, 2026	Director	FARRELL PETER C	January 7, 2026	Sold	2000	248.83	497.7k
January 8, 2026	Director	Farrell Michael J.	January 7, 2026	Sold	4991	248.46	1.24M
January 8, 2026	Director	Farrell Michael J.	January 7, 2026	Bought	4991	146.34	730.4k

[Company Profile]

ResMed Inc. is a Delaware corporation formed in March 1994. The company is a global leader in the development, manufacture, distribution, and marketing of medical devices and cloud-based software applications. These applications diagnose, treat, and manage respiratory system diseases, including sleep apnea, chronic obstructive pulmonary disease, neuromuscular diseases, and other chronic conditions. The company’s products and solutions are designed to improve patients’ quality of life, reduce the impact of chronic disease, and lower healthcare costs, as healthcare systems worldwide continue to shift care from hospitals to home and lower-cost settings. The company’s cloud-based digital software health applications and devices are designed to deliver connected care, improving patients’ treatment outcomes and increasing customer efficiency.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes